

Figure S1. Cells accumulation in SubG₁ and G₂/M phases after a CLytA-DAAO, either free or bound to MNPs, and D-Ala treatment in RWP-1 pancreatic carcinoma cell line and SW-620 colorectal carcinoma cell line. Cells were treated with 2 U/mL CLytA-DAAO and 1 mM D-Ala for a short time (15-60 min) and then, treatment was removed replacing the medium. Cells were incubated for 24 h from the treatment addition were completed. Graph shows the percentage of cells \pm SD in subG₁ and G₂/M phases (n \geq 3). * indicates a p-value < 0.05 and ** < 0.01.




Figure S2. Differential effects between H₂O₂ and CLytA-DAAO treatment in IMIM-PC-2 pancreatic carcinoma cell line. A. Intracellular ROS increase after a treatment with 2 U/mL CLytA-DAAO and 1 mM D-Ala or 600 μM H₂O₂ for 20-120 min. Free radical production was determined through DCFH₂-DA probe and each treatment time had a control untreated that only contained the probe. Graph shows the fold change (FC) ± SD of fluorescent intensity with respect to the control (n ≥ 6). **B.** Variations in cell cycle distribution after a treatment with 2 U/mL CLytA-DAAO and 1 mM D-Ala or 600 μM H₂O₂ for 24 h. Graph shows the cells percentage ± SD in each phase of cell cycle after subtracting the cells percentage in the control untreated (n ≥ 3). **C.** Plasmatic membrane rupture after a treatment with 2 U/mL CLytA-DAAO and 1 mM D-Ala or 600 μM H₂O₂ for 24 h. Graph represents cell death percentage (mean ± SD) after subtracting cell death in the control untreated (n ≥ 3). ** indicates a p-value < 0.01 and *** a p-value < 0.001.




Figure S3. Gene expression analysis in patient samples performed with the UALCAN platform. Graphs show the expression of CAT (A), NFE2L2 (B) and GPX2 (C) in samples TGCA samples from normal tissue and tumoral tissue of colon adenocarcinoma (COAD), glioblastoma (GBM) and pancreatic adenocarcinoma (PAAD). * indicates a p-value < 0.05 and *** a p-value < 0.001.

